Vaccine to prevent repeat Staph (Staphylococcus aureus) infections
Multivalent Toxoid Vaccine for recurrent Staphylococccus aureus disease
A multivalent toxoid vaccine called IBT-V02 aims to protect adults who get recurrent Staph aureus infections by neutralizing the bacteria's toxins and strengthening immune responses.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Abvacc, INC. NIH-funded |
| Lab location | 1 site (Rockville, United States) |
| Project ID | NIH-11285431 on NIH RePORTER |
What this research studies
This project is developing a multicomponent "toxoid" vaccine (IBT-V02) designed to block Staph aureus toxins and boost antibody and T‑cell responses that help control infection. The team has tested the vaccine in animal models, including models of first-time and recurrent skin and soft tissue infections, and is moving the candidate toward advanced development. The approach focuses on toxin neutralization rather than only targeting bacterial surface proteins, because previous surface-antigen vaccines failed in human trials. If development proceeds, the program may include clinical testing at company or partner clinical sites.
Who could benefit from this research
Good fit: Adults (21 years and older) with a history of recurrent Staphylococcus aureus skin and soft tissue infections or frequent ER visits for staph infections would be the most likely candidates.
Not a fit: Children under 21, people with infections not caused by Staphylococcus aureus, or those with conditions that prevent vaccine responses (severe immunosuppression) may not benefit.
Why it matters
Potential benefit: If successful, the vaccine could reduce repeat Staph skin infections, lower hospital or ER visits, and cut the need for antibiotics.
How similar studies have performed: Prior vaccines targeting staph surface antigens failed in human trials, but preclinical work with this multivalent toxoid vaccine has shown protection in animal and recurrent infection models, while human efficacy is still unproven.
Where this research is happening
Rockville, United States
- Abvacc, INC. — Rockville, United States (Active)
Researchers
- Principal investigator: Aman, M Javad — Abvacc, INC.
- Study coordinator: Aman, M Javad
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.